Aandeel SGMT SAGIMET BIOSCIENCES INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Sagimet Biosciences Inc.

Aandelen

SGMT

US7867001049

slotkoers Nasdaq
Andere beurzen
 00:00:00 10-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
4,44 USD -2,84% Intraday-grafiek van Sagimet Biosciences Inc. +2,78% -18,08%
06/05 Sagimet Biosciences benoemt Thierry Chauche tot CFO MT
02/05 SAGIMET BIOSCIENCES INC. : HC Wainwright handhaaft koopadvies ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Sagimet Biosciences Names Thierry Chauche CFO
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer
Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Sagimet Biosciences Inc. Announces Management Changes
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Top Premarket Decliners
Sagimet Biosciences Prices $112.5 Million Common Stock Offering; Shares Fall Pre-Bell
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers SGMT
  4. Nieuws Sagimet Biosciences Inc.
  5. Andere talen